anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Idalopirdine
Trial phase: Phase 3
SMILES: Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 285
Group description: Idalopirdine adjunct to 10 mg Donepezil

Idalopirdine: Once daily, encapsulated tablets, orally
Eligibility criteria:
Inclusion Criteria:

The patient has a knowledgeable and reliable caregiver.
The patient is an outpatient.
The patient has probable AD.
The patient has mild to moderate AD.
Stable treatment with donepezil.
The patient, if a woman, must have had her last natural menstruation ≥24 months prior to baseline, OR be surgically sterile.
The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.

Exclusion Criteria:

The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.
The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.
The patient has evidence of clinically significant disease.
The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.

Other inclusion and exclusion criteria may apply.
Intervention: Idalopirdine
Trial phase: Phase 3
SMILES: Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 281
Group description: Idalopirdine adjunct to 20 mg Donepezil

Idalopirdine: Once daily, encapsulated tablets, orally
Eligibility criteria:
Inclusion Criteria:

The patient has a knowledgeable and reliable caregiver.
The patient is an outpatient.
The patient has probable AD.
The patient has mild to moderate AD.
Stable treatment with donepezil.
The patient, if a woman, must have had her last natural menstruation ≥24 months prior to baseline, OR be surgically sterile.
The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.

Exclusion Criteria:

The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.
The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.
The patient has evidence of clinically significant disease.
The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.

Other inclusion and exclusion criteria may apply.
Intervention: Idalopirdine
Trial phase: Phase 3
SMILES: Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 363
Group description: Idalopirdine adjunct to base treatment with an AChEI

Idalopirdine: Once daily, encapsulated tablets, orally
Eligibility criteria:
Inclusion Criteria:

The patient has a knowledgeable and reliable caregiver.
The patient is an outpatient.
The patient has probable AD.
The patient has mild to moderate AD.
Stable treatment with an AChEI.
The patient, if a woman, must have had her last natural menstruation ≥24 months prior to baseline, OR be surgically sterile.
The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.

Exclusion Criteria:

The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.
The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.
The patient has evidence of clinically significant disease.
The patient's current AChEI therapy is likely to be interrupted or discontinued during the study.
The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.

Other inclusion and exclusion criteria may apply.
Intervention: Betamethasone
Trial phase: Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 158
Group description: IBI-10090 low dose

IBI-10090
Eligibility criteria:
Inclusion Criteria:

The patient must provide written informed consent by signing the Informed Consent approved by the Institutional Review Board (IRB).
Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.
The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 (with glare testing, if necessary) in the study eye and better than 20/200 in the fellow eye.
The patient must be considered by the Investigator to have visual acuity potential greater than 20/30 in the study eye.
The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology.
A female patient of childbearing potential (premenopausal by medical history) must have a negative pregnancy test on Day 0 and be using an effective method of birth control (although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch) from Screening for the duration of the study.
The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel.

Key Exclusion Criteria:

Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0.
Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
Patients who have received any intravitreal corticosteroid delivery vehicle (e.g., Retisert, Ozurdex, Iluvien) in the study eye at any time.
Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
Patients with an allergy or hypersensitivity to dexamethasone.
Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye).
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0.
Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening.
Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening.
Patients with planned intraocular or laser surgery in the study eye for the duration of the study.
Intervention: Betamethasone
Trial phase: Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 156
Group description: IBI-10090 med dose

IBI-10090
Eligibility criteria:
Inclusion Criteria:

The patient must provide written informed consent by signing the Informed Consent approved by the Institutional Review Board (IRB).
Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.
The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 (with glare testing, if necessary) in the study eye and better than 20/200 in the fellow eye.
The patient must be considered by the Investigator to have visual acuity potential greater than 20/30 in the study eye.
The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology.
A female patient of childbearing potential (premenopausal by medical history) must have a negative pregnancy test on Day 0 and be using an effective method of birth control (although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch) from Screening for the duration of the study.
The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel.

Key Exclusion Criteria:

Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0.
Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
Patients who have received any intravitreal corticosteroid delivery vehicle (e.g., Retisert, Ozurdex, Iluvien) in the study eye at any time.
Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
Patients with an allergy or hypersensitivity to dexamethasone.
Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye).
Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0.
Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening.
Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening.
Patients with planned intraocular or laser surgery in the study eye for the duration of the study.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 127
Group description: Transabdominal Plane Block with 0.25% bupivacaine
Eligibility criteria:
Inclusion Criteria:

age 18 and older
elective laparoscopic ventral (ventral, umbilical, incisional) hernia repair at Mount Sinai Hospital

Exclusion Criteria:

age younger than 18
allergic reaction to bupivacaine
allergic reaction to opioids
opioid substance abuse
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 127
Group description: Non Transabdominal Plane Block: Saline injection
Eligibility criteria:
Inclusion Criteria:

age 18 and older
elective laparoscopic ventral (ventral, umbilical, incisional) hernia repair at Mount Sinai Hospital

Exclusion Criteria:

age younger than 18
allergic reaction to bupivacaine
allergic reaction to opioids
opioid substance abuse
Intervention: Salsalate
Trial phase: Not Applicable
ATC code: N02BA06
SMILES: O=C(Oc1ccccc1C(=O)O)c1ccccc1O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 27
Group description: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner

salsalate: Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
Eligibility criteria:
Inclusion Criteria:

Healthy volunteers,
BMI 25-35kg/m2,
Without severe anemia, kidney, liver disease or any current GI ulcers or bleeding
Or on any medication contraindicated with salsalate

Exclusion Criteria:

Recent history of GI bleed or ulcers,
CVD or on anticoagulants
Severe kidney or liver disease
Allergies to aspirin
Taking aspirin or anti inflammatory medication on a regular basis and cannot be taken off for the duration of the study
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Exparel infiltrated into wound and chest tube sites

Exparel infiltration: Exparel infiltrated into wound and chest tube sites
Eligibility criteria:
Inclusion Criteria:

Patients aged 18-75 years inclusive and American Society of Anesthesiologists physical status 2-4.
Undergoing minimally invasive cardiac surgery.
Subjects must be physically and mentally able to participate in the study and complete all study assessments.
Subjects must be able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the proposed components of thoracotomy and chest tube sites infiltration.

Exclusion Criteria:

History of hypersensitivity or idiosyncratic reactions to amide-type local anesthetics
Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful performance of a thoracotomy and chest tube sites infiltration.
Any subject who in the opinion of the Investigator, might be harmed or be a poor candidate for participation in the study.
Any subject, who in the opinion of the Investigator, is on chronic pain medicine, including large doses of nonsteroidal antiinflammatory drugs.
Subjects who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000

Bupivacaine: 30mL of Bupivicaine 0.20% with epinephrine 1:300,000
Eligibility criteria:
Inclusion Criteria:

patients who are presenting for ACL reconstruction
candidates for peripheral nerve blocks patients
ASA 1-3

Exclusion Criteria:

Patient refusal
ASA Classification of 4 or higher
Pre-existing neuropathy in the femoral or sciatic distribution
Coagulopathy
Infection at the site
Non-English speaking or non-reading patients
Chronic opioid use (>3months)
Pregnancy
Any other contra-indication to regional anesthesia
Failed femoral nerve block
Sciatic nerve block placed due to severe pain not managed by intravenous and oral agents.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline

Preservative free normal saline: Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
Eligibility criteria:
Inclusion Criteria:

patients who are presenting for ACL reconstruction
candidates for peripheral nerve blocks patients
ASA 1-3

Exclusion Criteria:

Patient refusal
ASA Classification of 4 or higher
Pre-existing neuropathy in the femoral or sciatic distribution
Coagulopathy
Infection at the site
Non-English speaking or non-reading patients
Chronic opioid use (>3months)
Pregnancy
Any other contra-indication to regional anesthesia
Failed femoral nerve block
Sciatic nerve block placed due to severe pain not managed by intravenous and oral agents.
Intervention: Hydromorphone
Trial phase: Phase 4
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.

Hydromorphone: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
Eligibility criteria:
Inclusion Criteria:

Women presenting for elective cesarean delivery with no major co-morbidities, including pregnancy induced co-morbidities (e.g. pre-eclampsia)
Singleton gestation at term (37-42 weeks)
Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria:

Current or historical evidence of clinically significant medical disease or condition
Any contraindication to the administration of a spinal technique for anesthesia
History of hypersensitivity or idiosyncratic reaction to opioid medications
Chronic pain syndrome or current regular opioid use
Evidence of anticipated fetal anomalies
Allergy or intolerance to Tylenol, ketorolac, ibuprofen, or oxycodone
BMI > 40
Intervention: Morphine
Trial phase: Phase 4
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 42
Group description: Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.

Morphine: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
Eligibility criteria:
Inclusion Criteria:

Women presenting for elective cesarean delivery with no major co-morbidities, including pregnancy induced co-morbidities (e.g. pre-eclampsia)
Singleton gestation at term (37-42 weeks)
Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria:

Current or historical evidence of clinically significant medical disease or condition
Any contraindication to the administration of a spinal technique for anesthesia
History of hypersensitivity or idiosyncratic reaction to opioid medications
Chronic pain syndrome or current regular opioid use
Evidence of anticipated fetal anomalies
Allergy or intolerance to Tylenol, ketorolac, ibuprofen, or oxycodone
BMI > 40
Intervention: Letrozole
Trial phase: Not Applicable
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Patients received Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue was used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
Eligibility criteria:
Inclusion Criteria:

Histologic Documentation of invasive breast cancer by core needle or incisional biopsy. Excess baseline biopsy tumor tissue sufficient to make three 5-micron sections must be available for molecular analyses as part of this study.
The invasive cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% staining of invasive cancer cells by IHC.
The invasive cancer must be human epidermal growth factor receptor 2 (HER2) negative (IHC 0-1+, or with a fluorescence in situ hybridization (FISH) ratio of <1.8 if IHC is 2+ or if IHC has not been done).
Clinical stage I-III invasive breast cancer with the intent to treat with surgical resection of the primary tumor. Tumor must be ≥ 2cm to provide adequate tissue.
Patients with multi-centric or bilateral disease are eligible if the target lesions meet the other eligibility criteria. Samples from all available tumors are requested for research purposes.
Women ≥ age 18, for whom adjuvant treatment with an aromatase inhibitor would be clinically indicated. Women must be either post-menopausal, or pre-menopausal having undergone oophorectomy.
Patients must meet the following clinical laboratory criteria:

Absolute neutrophil count (ANC)≥ 1000/mm3 and platelet count ≥ 75,000/mm3. Total bilirubin ≤ 1.5 X the upper limit of normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.

- Ability to give informed consent.

Exclusion Criteria:

Prior endocrine therapy for any histologically confirmed cancer is not allowed. Prior endocrine therapy that was administered ≥ 5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed.
Systemic drug treatment to induce ovarian suppression if woman is pre-menopausal.
Any other neoadjuvant therapy for breast cancer (i.e., treatment with any other anti-cancer agent besides Letrozole (10-21)days before surgical resection of the primary tumor).